123 related articles for article (PubMed ID: 31147837)
1. The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis.
Zhang L; Ren HW; Wu QL; Wu YJ; Song X
Pathol Oncol Res; 2020 Apr; 26(2):1137-1143. PubMed ID: 31147837
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
Yu Z; Xu F; Zou J
Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
[TBL] [Abstract][Full Text] [Related]
3. Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials.
Vale CL; Burdett S; Fisher DJ; Navani N; Parmar MK; Copas AJ; Tierney JF
Clin Lung Cancer; 2015 May; 16(3):173-182.e4. PubMed ID: 25547901
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced
Chen F; Chen N; Yu Y; Cui J
Front Oncol; 2020; 10():904. PubMed ID: 32714857
[No Abstract] [Full Text] [Related]
5. Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.
Li N; Yang L; Ou W; Zhang L; Zhang SL; Wang SY
PLoS One; 2014; 9(7):e102777. PubMed ID: 25029199
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: A meta-analysis.
Yang Y; Wang L; Li X; Zhang S; Yu J; Nie X; Liu W; Wu X; Zhang P; Li Y; Li A; Ai B
Thorac Cancer; 2022 Jan; 13(1):31-37. PubMed ID: 34859599
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of anlotinib with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated
Li T; Chang K; Qiu X; Lai Z; Luo Y; Chen J; Lv W; Lin Z; Pei X; Wu X; Wang X
Transl Lung Cancer Res; 2023 Jun; 12(6):1256-1263. PubMed ID: 37425401
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
[No Abstract] [Full Text] [Related]
9. Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Sakharkar P; Kurup S; Deb S; Assaad K; Gesinski D; Gayle EJ
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539522
[TBL] [Abstract][Full Text] [Related]
10. Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer.
Xiao N; He H; Wang J; Zhang L; Chow B; Feng F; Xu Y; Huang J; Zhou X; Dong R
J Evid Based Integr Med; 2021; 26():2515690X211010733. PubMed ID: 33926244
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials.
Liu R; Wei S; Zhang Q; Zhang X; Luo H; Tian J; Li Y; Ge L; Wang X
Medicine (Baltimore); 2019 Jul; 98(29):e16427. PubMed ID: 31335695
[TBL] [Abstract][Full Text] [Related]
12. Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis.
Kashizaki F; Chen H; Miyasaka A; Tsuchiya N; Yamada C; Okazaki S; Kaneko M; Kano T; Kameda Y; Kikuchi A; Yumoto K; Osawa H; Koizumi H; Takahashi K; Kaneko T
Clin Lung Cancer; 2024 Jan; 25(1):e52-e57.e2. PubMed ID: 37932180
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure.
Li X; Huang H; Sun Y; Jiang Q; Yu Y
Front Oncol; 2023; 13():1265236. PubMed ID: 37869096
[TBL] [Abstract][Full Text] [Related]
14. A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line Treatment With Monotherapy in Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation.
Zhao KX; Zhang YF; Zheng L; Pan YF; He ZH
Am J Clin Oncol; 2023 Dec; 46(12):551-558. PubMed ID: 37779240
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tyrosine kinase inhibitors in patients with advanced or metastatic sarcomas after prior chemotherapy: A meta-analysis.
Li W; Liu L; Liang Z; Lai H; Wu J; Zhang H; Fang C
Medicine (Baltimore); 2024 Mar; 103(11):e37423. PubMed ID: 38489731
[TBL] [Abstract][Full Text] [Related]
16. Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
Shimoda Y; Yoshida T; Miyakoshi J; Torasawa M; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
Cancer Immunol Immunother; 2023 Aug; 72(8):2613-2621. PubMed ID: 37062033
[TBL] [Abstract][Full Text] [Related]
17. Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism.
Liu SY; Zhou JY; Li WF; Sun H; Zhang YC; Yan HH; Chen ZH; Chen CX; Ye JY; Yang JJ; Zhou Q; Zhang XC; Wu YL
Clin Transl Med; 2020 Jan; 10(1):337-345. PubMed ID: 32508032
[TBL] [Abstract][Full Text] [Related]
18. Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs.
Tone M; Iwahori K; Shiroyama T; Futami S; Naito Y; Fukushima K; Miyake K; Koyama S; Hirata H; Nagatomo I; Wada H; Takeda Y; Kumanogoh A
Sci Rep; 2023 May; 13(1):8313. PubMed ID: 37221285
[TBL] [Abstract][Full Text] [Related]
19. Concomitant
Canale M; Petracci E; Delmonte A; Bronte G; Chiadini E; Ludovini V; Dubini A; Papi M; Baglivo S; De Luigi N; Verlicchi A; Chiari R; Landi L; Metro G; Burgio MA; Crinò L; Ulivi P
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32272775
[TBL] [Abstract][Full Text] [Related]
20. Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis.
Mo Z; Ye M; He H; Huang X; Guo W; Zhao Z; Li Y; Wei S
Clin Med Insights Oncol; 2023; 17():11795549231215968. PubMed ID: 38107371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
